cancer vaccine

A customized mRNA vaccine designed to fight aggressive skin cancer has delivered sustained protection over five years. Patients receiving the experimental treatment alongside standard immunotherapy saw their risk of cancer returning or dying drop by nearly 50 percent compared to those on immunotherapy alone. mRNA cancer vaccine – artistic impression. Image credit: Alius Noreika / AI […]

by Akaash Babar, Peking University edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Design and development of iVAC, which restores immunogenicity through checkpoint degradation-coupled antigen presentation. Credit: Nature (2026). DOI: 10.1038/s41586-025-09903-1 A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed

by The Mount Sinai Hospital edited by Lisa Lock, reviewed by Andrew Zinin Credit: Pixabay/CC0 Public Domain In a new study published in Cancer Immunology Research, scientists at the Icahn School of Medicine at Mount Sinai have developed a novel method to generate billions of rare immune cells known as conventional type I dendritic cells (cDC1s), potentially paving the way for

by University of Florida edited by Stephanie Baum, reviewed by Andrew Zinin Credit: CC0 Public Domain An experimental mRNA vaccine has boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to “wake up” the immune system against cancer. Published in Nature Biomedical Engineering, the University